Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(interferon gamma 1b)
107 results
  • StatPearls: Interferon [BOOK]
    . StatPearls Publishing: Treasure Island (FL) Khanna Niloufar R. NR California Northstate University Gerriets Valerie V California Northstate University College of Medicine BOOK
  • Interferons are currently used clinically to treat viral infections such as hepatitis C, cancers including non-Hodgkin’s lymphoma, and autoimmune diseases such as multiple sclerosis. Interferon lambda currently has no FDA approved uses, but researchers use it in research models of autoimmune diseases, cancers, and viral infections. The various types of interferons include interferon-gamma 1b, int…
  • Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis. [Journal Article]
    J Bone Miner Res. 2019 08; 34(8):1436-1445.Imel EA, Liu Z, … Econs MJ
  • In autosomal dominant osteopetrosis type 2 (ADO2) CLCN7 mutations cause impaired osteoclast function. Severe consequences include skeletal fragility despite high bone mass, osteomyelitis, osteonecrosis, bone marrow failure, and severe cranial nerve impingement. There is no effective medical treatment for ADO2. We recruited subjects with ADO2 into a 14-week, open-label, pilot clinical trial of int…
  • Drugs and Lactation Database (LactMed): Interferon Gamma-1b [BOOK]
    . National Library of Medicine (US): Bethesda (MD)BOOK
  • Interferon gamma is a normal component of human milk. No data are available on the use of exogenous interferon gamma 1b during breastfeeding. However, the amounts of the similar drugs, interferon alfa and interferon beta-1a, excreted into milk are very low. Any interferon in breastmilk is probably destroyed in the infant's gastrointestinal tract and not absorbed, except perhaps in neonates. Holde…
  • A rare complication of chronic granulomatous disease in a child: constrictive aspergillus pericarditis. [Case Reports]
    Turk Kardiyol Dern Ars. 2017 Oct; 45(7):660-663.Şişli E, Özdemir Şahan Y, … Atay Y
  • A 3-year-old girl with the diagnosis of chronic granulomatous disease (CGD) was hospitalized for bronchopneumonia and congestive heart failure. Her medical history included methylprednisolone medication for autoimmune gastric outlet obstruction. Computed tomography revealed pneumonic infiltrations and pericardial thickening. A pulsed-wave Doppler recording revealed E/A >1. During a pericardiectom…
  • IFN-γ for Friedreich ataxia: present evidence. [Journal Article]
    Neurodegener Dis Manag. 2015 Dec; 5(6):497-504.Wells M, Seyer L, … Lynch DR
  • IFN-γ-1b is currently US FDA approved as an orphan drug for the treatment of chronic granulomatous disease and severe malignant osteopetrosis. It is administered via subcutaneous injection and is a potential therapy for Friedreich ataxia (FRDA), a rare degenerative neurological condition. Ongoing Phase II and III trials in both adults and children with FRDA were preceded by a small Phase I, open-…
  • Inhaled Interferon and Diffusion Capacity in Idiopathic Pulmonary Fibrosis (IPF). [Randomized Controlled Trial]
    Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jun 22; 32(1):37-42.Skaria SD, Yang J, … Smaldone GC
  • CONCLUSIONS: DLCO was significantly improved following inhaled (IFN-γ) as treatment for IPF. Our data suggest that previous studies utilizing parenteral IFN-γ may have failed because of the mode of delivery. Future randomized, controlled, phase 3 trials, comparing the difference in PFT behavior (specifically DLCO) longitudinally may be more sensitive to drug effect and serve as a valuable clinical endpoint.
  • Interferon Gamma, but not Calcitriol Improves the Osteopetrotic Phenotypes in ADO2 Mice. [Journal Article]
    J Bone Miner Res. 2015 Nov; 30(11):2005-13.Alam I, Gray AK, … Econs MJ
  • ADO2 is a heritable osteosclerotic disorder that usually results from heterozygous missense dominant negative mutations in the chloride channel 7 gene (CLCN7). ADO2 is characterized by a wide range of features and severity, including multiple fractures, impaired vision due to secondary bony overgrowth and/or the lack of the optical canal enlargement with growth, and osteonecrosis/osteomyelitis. T…
  • Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration. [Journal Article]
    J Pharm Sci. 2015 Apr; 104(4):1421-30.Mcleod VM, Chan LJ, … Kaminskas LM
  • The utility of inhaled protein therapeutics to treat lung-resident diseases is limited by protein degradation in the lungs and rapid clearance. This study therefore aimed to evaluate the impact of PEGylation on the lung and systemic exposure of interferon (IFN) α2 after intratracheal administration to rats. An inverse correlation was observed between PEG chain length and systemic exposure, where …
  • Open-label pilot study of interferon gamma-1b in Friedreich ataxia. [Clinical Trial]
    Acta Neurol Scand. 2015 Jul; 132(1):7-15.Seyer L, Greeley N, … Lynch DR
  • CONCLUSIONS: Interferon gamma-1b improved FARS scores without a clear relationship to changes in frataxin levels. Larger, longer placebo-controlled trials including biochemical assessments in affected tissues are necessary to evaluate fully the efficacy and utility of IFN-γ in FRDA.
  • Novelty in treatment of pulmonary fibrosis: pulmonary hypertension drugs and others. [Review]
    Cardiovasc Hematol Agents Med Chem. 2013 Sep; 11(3):169-78.Correale M, Totaro A, … Brunetti ND
  • Idiopathic pulmonary fibrosis (IPF) is a chronic condition of unknown etiology with deteriorating respiratory function leading to respiratory failure. Corticosteroids, alone or in combination with immunosuppressive drugs such as azathioprine, colchicine, and cyclophosphamide, have been used with limited success. Interferon-gamma-1b showed a significant improvement in pulmonary function only in on…
  • Clinical trials of investigational agents for IPF: a review of a Cochrane report. [Review]
    Respir Res. 2013; 14 Suppl 1:S4.Richeldi L
  • The magnitude of treatment effect can be assessed by a number of methods. One reliable method of collectively analysing data from randomised clinical trials is that used in Cochrane reviews. These systematic reviews identify and analyse the available evidence using the reliable method of meta-analysis. These often combine data from studies to provide robust evaluations of overall treatment effect…
  • Evidence-based treatment strategies in idiopathic pulmonary fibrosis. [Review]
    Eur Respir Rev. 2013 Jun 01; 22(128):163-8.Behr J
  • Recently updated guidelines have provided revised recommendations, based on the GRADE criteria, for the diagnosis and pharmacological and non-pharmacological management of patients with idiopathic pulmonary fibrosis (IPF). Cochrane reviews are also a highly respected and reliable source of evidence-based information that identify and analyse all available data of overall treatment effects from ap…
New Search Next